JP2020517692A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517692A5 JP2020517692A5 JP2019557872A JP2019557872A JP2020517692A5 JP 2020517692 A5 JP2020517692 A5 JP 2020517692A5 JP 2019557872 A JP2019557872 A JP 2019557872A JP 2019557872 A JP2019557872 A JP 2019557872A JP 2020517692 A5 JP2020517692 A5 JP 2020517692A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- item
- genetically modified
- modified
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023072284A JP7526312B2 (ja) | 2017-04-27 | 2023-04-26 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
| JP2024115656A JP2024153703A (ja) | 2017-04-27 | 2024-07-19 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491151P | 2017-04-27 | 2017-04-27 | |
| US62/491,151 | 2017-04-27 | ||
| PCT/US2018/029993 WO2018201071A1 (en) | 2017-04-27 | 2018-04-27 | B cells for in vivo delivery of therapeutic agents and dosages thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023072284A Division JP7526312B2 (ja) | 2017-04-27 | 2023-04-26 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517692A JP2020517692A (ja) | 2020-06-18 |
| JP2020517692A5 true JP2020517692A5 (https=) | 2021-05-20 |
Family
ID=63919297
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019557872A Withdrawn JP2020517692A (ja) | 2017-04-27 | 2018-04-27 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
| JP2023072284A Active JP7526312B2 (ja) | 2017-04-27 | 2023-04-26 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
| JP2024115656A Pending JP2024153703A (ja) | 2017-04-27 | 2024-07-19 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023072284A Active JP7526312B2 (ja) | 2017-04-27 | 2023-04-26 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
| JP2024115656A Pending JP2024153703A (ja) | 2017-04-27 | 2024-07-19 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220193129A1 (https=) |
| EP (1) | EP3615045A4 (https=) |
| JP (3) | JP2020517692A (https=) |
| CN (1) | CN110709090A (https=) |
| AU (2) | AU2018256887B2 (https=) |
| BR (1) | BR112019022473A2 (https=) |
| CA (1) | CA3061048A1 (https=) |
| NZ (1) | NZ758331A (https=) |
| WO (1) | WO2018201071A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020084034A1 (en) | 2018-10-26 | 2020-04-30 | F. Hoffmann-La Roche Ag | Multispecific antibody screening method using recombinase mediated cassette exchange |
| WO2020197984A1 (en) | 2019-03-22 | 2020-10-01 | Albany Medical College | Methods for improving cognitive function |
| CN110499336B (zh) * | 2019-08-23 | 2021-10-12 | 华南农业大学 | 一种利用小分子化合物提高基因组定点修饰效率的方法 |
| CN115003314A (zh) * | 2019-11-27 | 2022-09-02 | 得克萨斯大学体系董事会 | B细胞的大规模组合car转导和crispr基因编辑 |
| WO2022094284A1 (en) * | 2020-10-30 | 2022-05-05 | Immusoft Corporation | Methods of administering genetically modified b cells for in vivo delivery of therapeutic agents |
| WO2022225862A1 (en) * | 2021-04-19 | 2022-10-27 | Walking Fish Therapeutics | Methods of b cell expansion for use in cell therapy |
| TW202423959A (zh) * | 2022-08-24 | 2024-06-16 | 美商步行魚醫療公司 | 用於治療法布瑞氏症(fabry disease)之組成物及方法 |
| WO2024220446A2 (en) * | 2023-04-17 | 2024-10-24 | Be Biopharma, Inc. | Engineered cell preparations for treatment of hemophilia |
| WO2024220447A2 (en) * | 2023-04-17 | 2024-10-24 | Be Biopharma, Inc. | Engineered cell preparations for treatment of niemann pick b disease |
| WO2025106856A1 (en) | 2023-11-15 | 2025-05-22 | Immusoft Corporation | Migratory modified differentiated b cells for cancer therapy |
| WO2026085108A2 (en) | 2024-10-14 | 2026-04-23 | Immusoft Corporation | B cell compositions and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101426523B (zh) * | 2006-04-27 | 2013-03-27 | 财团法人首尔大学校产学协力财团 | 基于负载了天然杀伤t细胞的配体、和抗原的b细胞的疫苗 |
| AU2016202625A1 (en) * | 2007-07-27 | 2016-05-19 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-iduronidase activity in the CNS |
| US9074223B2 (en) * | 2010-01-08 | 2015-07-07 | Immusoft Corporation | Vectors and methods for transducing B cells |
| WO2014152832A1 (en) * | 2013-03-14 | 2014-09-25 | Immusoft Corporation | Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors |
| CN112851769A (zh) * | 2014-01-27 | 2021-05-28 | 分子模板公司 | 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽 |
| DK3234107T3 (da) * | 2014-12-19 | 2022-10-17 | Immusoft Corp | B-celler til in vivo-levering af terapeutiske midler |
| CA2981077A1 (en) * | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| HK1256341A1 (zh) * | 2015-05-15 | 2019-09-20 | 明尼苏达大学董事会 | 用於治疗性递送到中枢神经系统的腺相关物 |
| EP3765601A1 (en) * | 2018-03-16 | 2021-01-20 | Immusoft Corporation | B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength |
-
2018
- 2018-04-27 BR BR112019022473-4A patent/BR112019022473A2/pt unknown
- 2018-04-27 AU AU2018256887A patent/AU2018256887B2/en active Active
- 2018-04-27 JP JP2019557872A patent/JP2020517692A/ja not_active Withdrawn
- 2018-04-27 CN CN201880037089.5A patent/CN110709090A/zh active Pending
- 2018-04-27 US US16/607,962 patent/US20220193129A1/en active Pending
- 2018-04-27 EP EP18790427.1A patent/EP3615045A4/en active Pending
- 2018-04-27 NZ NZ758331A patent/NZ758331A/en unknown
- 2018-04-27 WO PCT/US2018/029993 patent/WO2018201071A1/en not_active Ceased
- 2018-04-27 CA CA3061048A patent/CA3061048A1/en active Pending
-
2023
- 2023-04-26 JP JP2023072284A patent/JP7526312B2/ja active Active
-
2024
- 2024-07-19 JP JP2024115656A patent/JP2024153703A/ja active Pending
-
2025
- 2025-04-09 AU AU2025202508A patent/AU2025202508A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517692A5 (https=) | ||
| Wang et al. | Transcription factors associated with IL-15 cytokine signaling during NK cell development | |
| JP7495695B2 (ja) | 幹細胞の免疫制御作用を調節する方法 | |
| CN111658670B (zh) | 溶瘤腺病毒载体与过继t细胞治疗组合物及其用途 | |
| CN106659742B (zh) | 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞 | |
| US20200199189A1 (en) | Cytokine Combination | |
| CN102174479B (zh) | 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用 | |
| US12409217B2 (en) | Administering a lymphocytic choriomeningtitis virus (LCMV) with improved tumor regression properties | |
| Wang et al. | Viral vectors expressing interleukin 2 for cancer immunotherapy | |
| CN107793482A (zh) | 嵌合抗原受体及其基因和重组表达载体、car133‑nkt 细胞及其制备方法和应用 | |
| JP2023138660A5 (https=) | ||
| JPH07503455A (ja) | 癌のリンホカイン遺伝子療法 | |
| AU2020242520B2 (en) | Method for the expansion and differentiation of T lymphocytes and NK cells in adoptive transfer therapies | |
| CN106520778A (zh) | 改造的白介素12及其在制备治疗肿瘤的药物中的用途 | |
| JP2021515576A5 (https=) | ||
| JPH09508116A (ja) | 末梢血単核細胞溶解活性を刺激するためのｉｌ−１０の使用 | |
| US20060153805A1 (en) | Viral vectors and the use of the same for gene therapy | |
| JP6687246B2 (ja) | 改変型免疫細胞、改変型免疫細胞の製造方法、およびこれらの利用 | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| WO2018009506A1 (en) | Erythroid-specific promoter and method of use thereof | |
| US20180066253A1 (en) | Methods and compositions for modifying endothelial cells | |
| JP2023548118A5 (https=) | ||
| US7323450B2 (en) | Complex immuno-gene medical composition for inhibiting tumor cells | |
| RU2019136194A (ru) | В-клетки для доставки терапевтических средств in vivo и их дозы | |
| Kerzel | L’IFN-alpha secreto da macrofagi ingegnerizzati in vivo riduce le metastasi al fegato e induce l’attivazione di processi contro regolatori che ne limitano l’efficacia |